These findings will provide crucial mechanistic insights into OC’s translational potential as a precision-targeted modulator of PAR-2-driven inflammation in CRC, establishing a robust foundation for future clinical investigations and therapeutic development. This evidence concerns the gene F2RL1 and colorectal carcinoma.